Cardinal Health (NYSE: CAH), a leading pharmaceuticals distributor, on Wednesday reported an increase in revenues and adjusted profit for the fourth quarter of 2024.
Fourth quarter revenue increased 12% year-over-year to $59.9 billion, mainly reflecting strong sales growth in the core business segmentRevenue for the Pharmaceutical and Specialty Solutions segment increased 13% to $55.6 billion in Q4The Global Medical Products and Distribution segment increased by 2% to $3.1 billion during the three monthsOperating earnings more than tripled to $401 million in the fourth quarterNet income, on a reported basis, was $235 million or $0.96 per share in Q4, vs. a loss of $56 million or $0.22 per share a year earlierAdjusted earnings increased 29% to $1.84 per share from $1.43 per share in the prior-year quarterIn the full fiscal year, operating cash flow and adjusted free cash flow reached all-time highs of $3.8 billion and $3.9 billion, respectivelyThe company raised adjusted EPS guidance for fiscal 2025 to $7.55-$7.70 from the previous forecast of ‘at least’ $7.50
The post Earnings Summary: Highlights of Cardinal Health’s (CAH) Q4 2024 results first appeared on AlphaStreet.
—
Blog powered by G6
Disclaimer! A guest author has made this post. G6 has not checked the post. its content and attachments and under no circumstances will G6 be held responsible or liable in any way for any claims, damages, losses, expenses, costs or liabilities whatsoever (including, without limitation, any direct or indirect damages for loss of profits, business interruption or loss of information) resulting or arising directly or indirectly from your use of or inability to use this website or any websites linked to it, or from your reliance on the information and material on this website, even if the G6 has been advised of the possibility of such damages in advance.
For any inquiries, please contact [email protected]
